ClinicalTrials.gg
TerminatedNCT00638963STOPUpdated Jun 14, 2017Results posted

Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

A Phase 2 interventional study of temozolomide in Breast Neoplasm, Brain Neoplasm and Second Neoplasm, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Why this study was terminated
Terminated due to poor accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing temozolomide in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Temozolomide · Breast Neoplasms.

Started
2008
with 1 other
Phase 2
7 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing temozolomide in Breast Neoplasms, this one is one of 2 that started in 2008, is one of 7 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 10 studies testing temozolomide in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing temozolomide in Breast Neoplasms as a file.
02

Study summary

The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.

Read the detailed description

Breast cancer is the second most common cause of brain metastases. Overall survival after the development of brain metastases tends to be poor (6-8 months). Over-expression of Human Epidermal Growth Factor Receptor 2 (HER-2/neu), negative estrogen receptor, and young age at diagnosis seem to be indicators of high risk for brain metastases. Temozolomide may be a good candidate for prophylactic chemotherapy because of its ability to cross the blood-brain-barrier, achieving high concentrations in the central nervous system (CNS).

03

Conditions studied

  • Breast Neoplasm
  • Brain Neoplasm
  • Second Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of breast cancer.
  • Participants must have completed of metastatic chemotherapy and have achieved complete or partial response or disease stability for at least 6 months from the first confirmation of disease stabilization.
  • No clinical sign of brain progression.
  • At least one of the following 3 conditions: +++, Young age (\< 50 years), and/or estrogen receptor (ER)-/progesterone receptor (PgR)-
  • (ECOG) performance status ≤2.
  • ≥3 months.
  • Neutrophils ≥1.5 x 10\^9/L, ≥100 x 10\^9/L, ≥9 g/dL, lymphocytes ≥1 x 10\^9/L.
  • level either normal or \<1.5 x (upper limit of normal).
  • (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤2.5 x ULN (≤5 x ULN if liver metastases are present).
  • Serum creatine \<1.5 x ULN.
  • Effective if the risk of conception exists.

Exclusion criteria

Exclusion Criteria:

  • Concurrent chronic systemic immune therapy not indicated in the study protocol.
  • Any agent(s) within 4 weeks prior to entry.
  • Participants that have completed 2nd, 3rd, or 4th line chemotherapy or participant in active chemotherapy treatment.
  • coronary artery disease or a history of a myocardial infarction within the last 12 months.
  • Acute or sub acute intestinal occlusion or history of inflammatory bowel disease.
  • Known Grade 3 or Grade 4 allergic reaction to any of the components of the treatment.
  • Known drug abuse/alcohol abuse.
  • Legal incapacity or limited legal capacity.
  • Medical or psychological condition which in the opinion of the investigator would not permit the participant to complete the study or sign meaningful .
  • Women who are pregnant or breastfeeding.
  • Any concurrent other than non-melanoma skin cancer, or carcinoma in situ of the cervix (participants with a previous malignancy but without evidence of disease for ≥5 years will be allowed to enter the trial).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Temozolomide

    Drug: temozolomide

  • No intervention
    Observational

Interventions

  • Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Recurrence of Brain Metastases

    The analysis could not be performed due to low enrollment.

    Time frame: 1 Year

Secondary outcomes

  1. Number of Days With Progression-free Survival (PFS)

    PFS was defined as the time interval from randomization to objective tumor progression or death from any cause. The analysis could not be performed due to low enrollment.

    Time frame: 24, 38, and 52 weeks

  2. Number of Days With Disease-free Survival (DFS)

    DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant). The analysis could not be performed due to low enrollment.

    Time frame: 24, 38, and 52 weeks

  3. Number of Days With Distant Disease-free Survival (DDFS)

    DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain). The analysis could not be performed due to low enrollment.

    Time frame: 24, 38, and 52 weeks

  4. Number of Days With Brain Recurrence-free Survival (BRFS)

    BRFS was defined as the time interval from randomization to the appearance of brain metastases. The analysis could not be performed due to low enrollment.

    Time frame: 24,38, and 52 weeks

  5. Number of Days on Temozolomide Treatment

    This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

    Time frame: Baseline to 24 Weeks

  6. Total Dose of Temozolomide Taken

    This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

    Time frame: Baseline to 24 Weeks

  7. Number of Participants Who Had at Least One Dose Reduction During Treatment

    This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

    Time frame: Baseline to 24 Weeks

  8. Number of Participants Who Had at Least One Treatment Omission During Treatment

    This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

    Time frame: Baseline to 24 Weeks

  9. Number of Participants Who Completed the Third Cycle of Treatment

    This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

    Time frame: Baseline to 24 Weeks

07

Results

Posted Jul 22, 2011
Limitations and caveats
The primary outcome measure and the survival analyses could not be analyzed due to the low enrollment.

Participant flow

Participant flow — Overall Study
MilestoneTemozolomideObservational
Started33
Completed23
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercent of Participants With Recurrence of Brain Metastases

The analysis could not be performed due to low enrollment.

Time frame:
1 Year

No measurements were reported for this outcome.

SecondaryNumber of Days With Progression-free Survival (PFS)

PFS was defined as the time interval from randomization to objective tumor progression or death from any cause. The analysis could not be performed due to low enrollment.

Time frame:
24, 38, and 52 weeks

No measurements were reported for this outcome.

SecondaryNumber of Days With Disease-free Survival (DFS)

DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant). The analysis could not be performed due to low enrollment.

Time frame:
24, 38, and 52 weeks

No measurements were reported for this outcome.

SecondaryNumber of Days With Distant Disease-free Survival (DDFS)

DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain). The analysis could not be performed due to low enrollment.

Time frame:
24, 38, and 52 weeks

No measurements were reported for this outcome.

SecondaryNumber of Days With Brain Recurrence-free Survival (BRFS)

BRFS was defined as the time interval from randomization to the appearance of brain metastases. The analysis could not be performed due to low enrollment.

Time frame:
24,38, and 52 weeks

No measurements were reported for this outcome.

SecondaryNumber of Days on Temozolomide Treatment

This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

Time frame:
Baseline to 24 Weeks
Reported as:
Mean · Days
Number of Days on Temozolomide Treatment
DaysTemozolomide
Number of Days on Temozolomide Treatment75 ± 65.82
SecondaryTotal Dose of Temozolomide Taken

This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

Time frame:
Baseline to 24 Weeks
Reported as:
Mean · Milligrams
Total Dose of Temozolomide Taken
MilligramsTemozolomide
Total Dose of Temozolomide Taken9791.9 ± 8732.0
SecondaryNumber of Participants Who Had at Least One Dose Reduction During Treatment

This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

Time frame:
Baseline to 24 Weeks
Reported as:
Number · Participants
Number of Participants Who Had at Least One Dose Reduction During Treatment
ParticipantsTemozolomide
Number of Participants Who Had at Least One Dose Reduction During Treatment3
SecondaryNumber of Participants Who Had at Least One Treatment Omission During Treatment

This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

Time frame:
Baseline to 24 Weeks
Reported as:
Number · Participants
Number of Participants Who Had at Least One Treatment Omission During Treatment
ParticipantsTemozolomide
Number of Participants Who Had at Least One Treatment Omission During Treatment2
SecondaryNumber of Participants Who Completed the Third Cycle of Treatment

This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.

Time frame:
Baseline to 24 Weeks
Reported as:
Number · Participants
Number of Participants Who Completed the Third Cycle of Treatment
ParticipantsTemozolomide
Number of Participants Who Completed the Third Cycle of Treatment2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide—0/3 (0%)2/3 (66.7%)
Observational—0/3 (0%)2/3 (66.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTemozolomideObservational
NauseaGastrointestinal disorders2/30/3
DiarrhoeaGastrointestinal disorders1/30/3
VomitingGastrointestinal disorders1/30/3
AstheniaGeneral disorders1/30/3
Chest painGeneral disorders0/31/3
Influenza like illnessGeneral disorders1/30/3
PyrexiaGeneral disorders1/30/3
MyalgiaMusculoskeletal and connective tissue disorders1/30/3
InsomniaPsychiatric disorders1/30/3
Vulvovaginal drynessReproductive system and breast disorders0/31/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TemozolomideObservationalTotal
<=18 years000
Between 18 and 65 years336
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)TemozolomideObservationalTotal
Female336
Male000
Region of Enrollment
Region of Enrollment(participants)TemozolomideObservationalTotal
Italy336
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2008 to primary completion in Jun 2010, 20 months.

Results were first posted in Jul 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2008
First posted
Mar 19, 2008
StartActual
Oct 2, 2008
Primary completionActual
Jun 30, 2010
CompletionActual
Jun 30, 2010
Results first posted
Jul 22, 2011
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00638963
Responsible party
Sponsor
First posted
Mar 19, 2008
Start date
Oct 2, 2008
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010
Results posted
Jul 22, 2011
Last update
Jun 14, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion